A randomised trial comparing the safety and efficacy of the Zoladex 10.8 mg depot, administered every 12 weeks, to that of the Zoladex 23,6 mg depot, administered every 4 weeks, in patients with advanced prostate cancer

Autor: Dijkman, G.A., Debruyne, F.M.J., Fernandez del Moral, P., Plasman, J.W.M.H., Hoefakker, J.W., Idema, J.G., Sykes, M.
Jazyk: angličtina
Rok vydání: 1995
Zdroj: Medisch Contact, 27, 1, pp. 43-46
Medisch Contact, 27, 43-46
ISSN: 0025-8245
Popis: Item does not contain fulltext
Databáze: OpenAIRE